Month: November 2020

New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender

 Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by...

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association’s Virtual Scientific Sessions 2020

error: Content is protected !!